Improving CAR-T cell therapy for kidney cancer
Official title: Advancing Next Generation CAR-T cells for Renal Cell Carcinoma
Funded at Cellinfinity Bio, INC. · NIH-11007712 · Data updated 2026-11-12
This study is looking at ways to make CAR-T cell therapy better for people with kidney cancer by using new technology to improve how these immune cells fight tumors, which could lead to more effective treatment options for patients.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cellinfinity Bio, INC. NIH-funded |
| Lab location | 1 site (Milford, United States) |
| Project start | September 18, 2024 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $400,000 |
| NIH project number | 1R44CA295407-01 |
| Project ID | NIH-11007712 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults diagnosed with Renal Cell Carcinoma who have not responded well to existing treatments.
✕Less likely to help
Patients with non-cancerous kidney conditions or those who do not have Renal Cell Carcinoma may not benefit from this research.
What this research studies
This research focuses on enhancing CAR-T cell therapy specifically for patients with Renal Cell Carcinoma (RCC), a common type of kidney cancer. The team is utilizing advanced CRISPR technology to identify genetic modifications that can improve the effectiveness of CAR-T cells against solid tumors. By modifying T cells to enhance their immune response and persistence, the goal is to overcome current limitations of CAR-T therapy in treating RCC. Patients may benefit from a more effective treatment option that could lead to better outcomes in managing their cancer.
Why it matters
Potential benefit: If successful, this research could provide a more effective CAR-T cell therapy option for patients with Renal Cell Carcinoma.
How similar studies have gone: Previous research has shown promising results in enhancing CAR-T cell therapy for hematological malignancies, but this approach for solid tumors like RCC is still being explored.
Where this research is happening
-
Cellinfinity Bio, INC.
Milford, United States Active
Researchers
- Principal investigator: Patel, Premal — Cellinfinity Bio, INC.
- Study coordinator: Patel, Premal
Related research
Other NIH-funded projects on the same topics.
-
Understanding how kidney cancer spreads to bone and how to fight it
A patient-focused look at how clear cell renal cell carcinoma spreads to bone and how new treatments might help people with advanced disease.
-
Improve precision medicine for kidney cancer in people of African descent
A research project will explore why kidney cancer affects people of African ancestry differently and how to use genomics to guide better treatments.
-
Engineering immunogenic cell death to boost melanoma and kidney cancer therapy
This grant supports research aimed at making melanoma and kidney cancer cells die in a way that triggers a stronger immune response in patients.
-
Prognostic test to predict metastasis in clear cell kidney cancer
A new 12-marker biomarker test for people with clear cell renal cell carcinoma may help doctors predict which patients are at higher risk of metastasis.
-
Defining metabolic targets in kidney cancer for new treatments
A cancer-focused project is exploring how kidney cancer uses metabolism so doctors can find new, targeted ways to treat it.
-
Targeting HIF2 in kidney cancer: a new approach for clear cell RCC
A kidney cancer research program tests whether blocking HIF2 can slow or stop tumors in people with clear cell renal cell carcinoma.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.